The HSP90 Inhibitor, AT13387, Is Effective against Imatinib-Sensitive and -Resistant Gastrointestinal Stromal Tumor ModelsTomoko Smyth, Nicola G. Wallis, Rachel Donsky et al.|Molecular Cancer Therapeutics|2012Cited by 59
Abstract 607: Genomic analyses and novel models validate CDK4 as a therapeutic target in imatinib-resistant dermatofibrosarcoma protuberansAdrián Mariño‐Enríquez, Jonathan A. Fletcher, Jeffrey T. Czaplinski et al.|Cancer Research|2015Cited by 0
Supplementary Figure Legend from The HSP90 Inhibitor, AT13387, Is Effective against Imatinib-Sensitive and -Resistant Gastrointestinal Stromal Tumor ModelsTomoko Smyth, Nicola G. Wallis, Thomas Van Looy et al.|Unknown|2023Cited by 0
Supplementary Figure 1 from The HSP90 Inhibitor, AT13387, Is Effective against Imatinib-Sensitive and -Resistant Gastrointestinal Stromal Tumor ModelsTomoko Smyth, Nicola G. Wallis, Thomas Van Looy et al.|Unknown|2023Cited by 0
Supplementary Figure Legend from The HSP90 Inhibitor, AT13387, Is Effective against Imatinib-Sensitive and -Resistant Gastrointestinal Stromal Tumor ModelsTomoko Smyth, Nicola G. Wallis, Thomas Van Looy et al.|Unknown|2023Cited by 0